CNP and coronary artery disorder: Our findings that circulating concentrations of the stable product of proCNP (NTproCNP) – nor the concentration of authentic CNP – did not change during standard (lipid reducing) doses of atorvastatin for periods of 7 days in healthy subjects, and beyond during an extended period of 6 months in those with CAD, lead us to conclude that in males, doses of the drug used in routine clinical practice do not affect plasma CNP products.